Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Addition of SGLT2 inhibitor with improved efficacy will be able to address demands of T2D market, says GlobalData

At the 57th annual European Association for the Study of Diabetes (EASD) 2021 meeting, results were presented for a 3-year prospective study. The study results demonstrated that sodium glucose cotransporter 2 inhibitor (SGLT2I), either empagliflozin (Jardiance) or dapagliflozin (Farxiga), are efficacious as part of a quadruple combination therapy with metformin, dipeptidyl peptidase-4 inhibitor (DPP-4I) and […]
Read more

Growth potential for India in innovation and R&D, says GlobalData

India has the third largest pharma market in the world by volume, according to research by GlobalData, placing it behind giants such as the US and China. The leading data and analytics company notes that India’s potent manufacturing capabilities, high export activity and large generics market have supported the country in grabbing ‘bronze place’. According […]
Read more

Improving diversity in clinical trials ensures public health strategies are appropriately tailored to all populations, says GlobalData

Data presented at the 14th AACR* Conference in early October revealing that black patients were significantly more likely to be excluded from pancreatic clinical trials than white counterparts is unfortunately not the only instance of this occurring, says GlobalData. The leading data and analytics company notes that there is an ever-growing concern of ethnic disparity […]
Read more

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty sees over 200% rise in sales forecasts for Q3 vs Q2, says GlobalData

The sales forecast for Pfizer/BioNTech’s COVID-19 vaccine Comirnaty has been upwardly adjusted by GlobalData due to anticipated demand for booster shots. The leading data and analytics company has increased its forecasts for Comirnaty’s sales by a phenomenal 190% and 228% in 2022 and 2023, respectively. The drug is now expected to see sales totalling $28.4bn […]
Read more

Opportunities remain for drug developers to address unmet needs in axillary hyperhidrosis therapeutics market, says GlobalData

The lack of available treatments for axillary hyperhidrosis (AH), a disease characterized by increased sweat production in the armpits, offers an opportunity for pharmaceutical and biotechnology companies, according to GlobalData, a leading data and analytics company. Mandana Emamzadeh, PhD, Pharma Analyst at GlobalData, comments: “GlobalData has identified several key unmet needs in the AH space, […]
Read more

Major depressive disorder market to reach $7.87bn in 8MM by 2029, with eight new pipeline products set to capture 62.9% of sales, says GlobalData

The prevalence of major depressive disorder (MDD) symptoms are expected to increase due to COVID-19-related stress, as patients struggled with a loss of personal freedom, conflicting messages from authorities and concerns with health security Increased activity is expected in digital therapeutics (DTx) as pharmaceutical companies aim to fill the unmet need of improved patient education […]
Read more

Valneva’s COVID-19 vaccine will be strong competition for AstraZeneca and J&J, says GlobalData

Following the news that Valneva’s COVID-19 vaccine showed superior neutralizing antibody levels and an equal seroconversion rate and protection against SARS-CoV-2, compared to AstraZeneca’s Vaxzevria; Philipp Rosenbaum, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Valneva’s promising initial Phase III data, with at least equal protection levels and […]
Read more

COVID-19 brings mixed fortunes for commercial dose CMOs, says GlobalData

The contract manufacturing industry for finished dose pharmaceuticals had the lowest growth rate in a decade in 2020, according to GlobalData estimates. The leading data and analytics company reveals that total commercial dose contract manufacturing organization (CMO) contract revenue in 2020 grew by only 2.4% over 2019 revenue. Adam Bradbury, Pharma Analyst at GlobalData, comments: […]
Read more

Arcutis may face challenges when marketing roflumilast despite commercial advantage, says GlobalData

Arcutis Biotherapeutics recently announced the submission of a New Drug Application (NDA) for its topical phosophodiesterase 4 (PDE4) inhibitor, roflumilast cream (ARQ-151), in the treatment of mild-to-severe plaque psoriasis (PsO). Despite having a potential commercial advantage as the first topical PDE4 inhibitor for an underserved PsO patient segment, GlobalData, a leading data and analytics company, […]
Read more

AbbVie likely to retain key position in axial spondyloarthritis digital marketing space in Japan, says GlobalData

Historically, anti-tumor necrosis factor (TNF) drugs were the key biologic therapies available in Japan for axial spondyloarthritis (axSpA) treatment. However, the overall competition with the new class of marketed biologics such as anti-IL-17 therapies and the marketed biosimilars is expected to impact the sales of leading drugs — AbbVie’s Humira and Janssen’s/Mitsubishi Tanabe’s Remicade. Against […]
Read more

Growing importance of AI in pharmaceutical industry is mirrored by steady rise in AI-related job postings, says GlobalData

There has been a strong increase of vacancies in artificial intelligence (AI) related jobs in the pharmaceutical sector this year, despite the impact of COVID-19, says GlobalData. According to the leading data and analytics company’s Jobs Analytics database, the number of AI-related job announcements tripled from over 1000 in Q3 2019 to more than 3,000 […]
Read more

Plaque psoriasis population to reach over 16.8 million by 2030 in the 7MM influenced by obesity, type 2 diabetes and smoking, says GlobalData

The number of individuals with diagnosed plaque psoriasis in the seven major markets (7MM*) is projected to increase from around 15,720,000 in 2020 to over 16,850,000 in 2030, at an annual growth rate (AGR) of 0.72% according to GlobalData, a leading data and analytics company. These increases are likely to subsequently increase the size of […]
Read more

Neurology digital therapeutics market in Japan nascent, but several opportunities exist, says GlobalData

Digital therapeutics (DTx) uses digital technology to remotely prevent, treat, or manage a wide range of conditions through data-driven interventions. The digital therapeutics market for neurological diseases in Japan is nascent but several opportunities exist, says GlobalData, a leading data and analytics company. Shionogi & Co Ltd, a partner of Akili Interactive (Akili), a prescription […]
Read more
1 … 56 57 58 59 60 … 110